1983-1987 Dr. Norman Bethune Medical University BD
1989-1992 Dr. Norman Bethune Medical University MD
1992-1996 Sun Yat-sen University Zhongshan School of Medicine Ph.D
1999–2005: Director, Genomic Drug Engineering Research Center of the Ministry of Education, Jinan University.
2005–2009: Deputy Director, National Engineering Research Center for Genetic Engineering Drugs.
2005–2012: Dean, School of Pharmaceutical Sciences, Wenzhou Medical University; Director, Zhejiang Provincial Key Laboratory of Biotechnology and Pharmaceutical Engineering.
2013– 2015: Vice President, Wenzhou Medical University.
2015–2018: President,Wenzhou University.
2018–Present: President, Wenzhou Medical University.
2021-Present: Chief Scientist, Oujiang Lab
Li Xiaokun primarily focuses on basic theoretical research and new drug development of protein drugs represented by growth factors, particularly the function, systematic theory, and new drug research of the fibroblast growth factor (FGFs) family proteins. He has pioneered the development of several Class I new drugs and Class III drug-loaded medical devices that promote tissue injury repair and regeneration, which are widely used in the treatment of burns, refractory ulcers, major disaster-related trauma, and military combat injuries . He discovered and systematically elucidated the mechanism linking the FGFs family proteins to metabolic diseases, proposing the "growth factor metabolic axis" theory. This work provides new insights for diagnosing and treating related metabolic diseases and lays an important foundation for developing new drugs that use growth factors to treat metabolic disorders
1999 | National Award for Science and Technology Progress, Third Class Prize | (Rank 3 Completer) |
2004 | National Award for Science and Technology Progress, Second Class Prize | (Rank 3 Completer) |
2009 | National Award for Technological Invention, Second Class Prize | (Rank 1 Completer) |
2015 | National Award for Science and Technology Progress, First Class Prize | (Rank 4 Completer) |
2018 | National Award for Science and Technology Progress, Second Class Prize | (Rank 1 Completer) |
2017 | Natural Science Award of the Ministry of Education, First Class Prize | (Rank 1 Completer) |
2012 | Natural Science Award of the Ministry of Education, Second Class Prize | (Rank 1 Completer) |
2003 | Natural Science Award of the Ministry of Education, First Class Prize | (Rank 1 Completer) |
2019 | Elected Academician of the Chinese Academy of Engineering | |
2023 | National Natural Science Award,Second Class Prize |
（1）alpha-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signaling.Nature,2018,553
(7689):461-466.(IF=70)
（2）Fibroblast Growth Factor 21 Prevents Atherosclerosis by Suppression of Hepatic Sterol Regulatory Element-Binding Protein-2 and Induction of Adiponectin in Mice.Circulation,2015,131(21):1861-71.(IF=40)
（3）FGF21 alleviates microvascular damage following limb ischemia/reperfusion injury by TFEB-mediated autophagy enhancement and anti-oxidative response.Signal Transduction and Targeted Therapy,2022;7(1):349.(IF=38)
（4）FGF1(Delta HBS) prevents diabetic cardiomyopathy by maintaining mitochondrial homeostasis and reducing oxidative stress via AMPK/Nur77 suppression.Signal Transduction and Targeted Therapy,2021,6(1):133.(IF=38)
（5）Adiponectin Mediates the Metabolic Effects of FGF21 on Glucose Homeostasis and Insulin Sensitivity in Mice.Cell Metabolism,2013,17(5):779-789.(IF=31)
